On Wednesday, advisory panel to the Food and Drug Administration recommended taking Makena, a drug for preventing premature births, off the market due to doubts about the drug’s effectiveness. Makena was fast-tracked 11 years ago to cut the risk of preterm birth, a leading cause of infant mortality. The 14-1 vote by the FDA’s Obstetrics, …
Continue reading “FDA advisory panel recommends revoking sale of preterm birth drug”